Cargando…

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity

BACKGROUND AND PURPOSE: Esophageal cancer incidence is increasing and is rarely curable. Hypoxic tumor areas cause resistance to conventional therapies, making them susceptible for treatment with hypoxia-activated prodrugs (HAPs). We investigated in vivo whether the HAP evofosfamide (TH-302) could i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spiegelberg, Linda, van Hoof, Stefan J., Biemans, Rianne, Lieuwes, Natasja G., Marcus, Damiënne, Niemans, Raymon, Theys, Jan, Yaromina, Ala, Lambin, Philippe, Verhaegen, Frank, Dubois, Ludwig J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Scientific Publishers 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913516/ https://www.ncbi.nlm.nih.gov/pubmed/31431383 http://dx.doi.org/10.1016/j.radonc.2019.06.034

Ejemplares similares

Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy
por: Olivo Pimentel, Veronica, et al.
Publicado: (2021)

Use of a Luciferase-Expressing Orthotopic Rat Brain Tumor Model to Optimize a Targeted Irradiation Strategy for Efficacy Testing with Temozolomide
por: Mowday, Alexandra M., et al.
Publicado: (2020)

The Sulfamate Small Molecule CAIX Inhibitor S4 Modulates Doxorubicin Efficacy
por: van Kuijk, Simon J. A., et al.
Publicado: (2016)

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
por: Spiegelberg, Linda, et al.
Publicado: (2019)

In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
por: Panth, Kranthi Marella, et al.
Publicado: (2016)

Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
por: van Kuijk, Simon J. A., et al.
Publicado: (2016)

Inter-observer variability of organ contouring for preclinical studies with cone beam Computed Tomography imaging
por: Lappas, Georgios, et al.
Publicado: (2022)

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
por: Rekers, Nicolle H., et al.
Publicado: (2018)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
por: Marcus, Damiënne, et al.
Publicado: (2021)

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

Mitochondrial Dysfunction Inhibits Hypoxia-Induced HIF-1α Stabilization and Expression of Its Downstream Targets
por: van Gisbergen, Marike W., et al.
Publicado: (2020)

Combining radiotherapy with immunotherapy: the past, the present and the future
por: Van Limbergen, Evert J, et al.
Publicado: (2017)

Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer
por: Sanduleanu, Sebastian, et al.
Publicado: (2020)

‘On the Spot’ Digital Pathology of Breast Cancer Based on Single-Cell Mass Spectrometry Imaging
por: Cuypers, Eva, et al.
Publicado: (2022)

Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells
por: Kazokaitė, Justina, et al.
Publicado: (2018)

E. coli nitroreductase NfsA is a reporter gene for non-invasive PET imaging in cancer gene therapy applications
por: Mowday, Alexandra Marie, et al.
Publicado: (2020)

Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology
por: van der Wiel, Alexander M. A., et al.
Publicado: (2022)

Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape
por: Hamis, Sara, et al.
Publicado: (2020)

Polyphenols as Potential Protectors against Radiation-Induced Adverse Effects in Patients with Thoracic Cancer
por: Prades-Sagarra, Èlia, et al.
Publicado: (2023)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

(18)F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model
por: Grkovski, Milan, et al.
Publicado: (2018)

Synergistic Effects of NOTCH/γ-Secretase Inhibition and Standard of Care Treatment Modalities in Non-small Cell Lung Cancer Cells
por: Sosa Iglesias, Venus, et al.
Publicado: (2018)

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
por: Larue, Ruben T. H. M., et al.
Publicado: (2016)

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
por: Jamieson, Stephen M.F., et al.
Publicado: (2023)

Efficient Secretion of Murine IL-2 From an Attenuated Strain of Clostridium sporogenes, a Novel Delivery Vehicle for Cancer Immunotherapy
por: Kubiak, Aleksandra M., et al.
Publicado: (2021)

[(18)F]VM4-037 MicroPET Imaging and Biodistribution of Two In Vivo CAIX-Expressing Tumor Models
por: Peeters, Sarah G. J. A., et al.
Publicado: (2015)

Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
por: Huang, Yan, et al.
Publicado: (2018)

Deep-learning and MR images to target hypoxic habitats with evofosfamide in preclinical models of sarcoma
por: Jardim-Perassi, Bruna V., et al.
Publicado: (2021)

Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis
por: Moreno Roig, Eloy, et al.
Publicado: (2018)

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()
por: Kumar, Sushil, et al.
Publicado: (2018)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
por: Liapis, Vasilios, et al.
Publicado: (2017)

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer
por: Yoon, Jeesun, et al.
Publicado: (2021)

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
por: Brenner, Andrew J., et al.
Publicado: (2021)

Treating colorectal peritoneal metastases with an injectable cytostatic loaded supramolecular hydrogel in a rodent animal model
por: Wintjens, Anne G. W. E., et al.
Publicado: (2023)

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models
por: Harms, Julia K., et al.
Publicado: (2019)

Hypoxia Imaging With PET Correlates With Antitumor Activity of the Hypoxia-Activated Prodrug Evofosfamide (TH-302) in Rodent Glioma Models
por: Stokes, Ashley M., et al.
Publicado: (2016)

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide
por: Lodi, Alessia, et al.
Publicado: (2022)

Distinct radiation responses after in vitro mtDNA depletion are potentially related to oxidative stress
por: van Gisbergen, Marike W., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_5kff2ksgog8kjs84hubefnqdvb